Pricing
Priced for a few accounts, not a crowd
Comparable biotech intelligence seats run $12k to $70k a year, and they start covering a drug once it is already in the clinic and attached to a ticker. Biodatica covers the years before that. Annual billing, cancel from your account.
Analyst
Solo investor or scout
$6,000/yr
The feed, dossiers, watchlists and email alerts, in the one therapeutic area you cover. Enough to run a beat on your own.
- Included: 1 therapeutic area, chosen by you
- Included: 200 rows per feed or screener query
- Included: Watch up to 100 companies
- Included: 1 seat
- Included: Full dossiers: crosswalk timeline, evidence, source filings
- Included: Instant email alerts on watched companies
- Included: Natural-language and structured screener
- Not included: No CSV export
- Not included: No API access
An Analyst seat covers one area. You can change it from your account later.
Billed annually. Cancel from your account.
Fund
Most fundsSeed and crossover funds
$24,000/yr
Every therapeutic area, the screener, CSV exports, and five seats. The whole graph, for a whole investment team.
- Included: Every therapeutic area
- Included: 1,000 rows per feed or screener query
- Included: Watch up to 1,000 companies
- Included: 5 seats
- Included: Full dossiers: crosswalk timeline, evidence, source filings
- Included: Instant email alerts on watched companies
- Included: Natural-language and structured screener
- Included: CSV exports
- Not included: No API access
Billed annually. Cancel from your account.
Feed / API
Pharma business development, quant and alt-data
Contact us
From $40,000/yr, scoped by conversation
The full API, the raw signal feed, custom alert rules, and priority on the entity-resolution queue for the names you care about. Sold on a call, because the scope is different every time.
- Included: Every therapeutic area
- Included: 5,000 rows per feed or screener query
- Included: Watch up to 10,000 companies
- Included: 25 seats
- Included: Full dossiers: crosswalk timeline, evidence, source filings
- Included: Instant email alerts on watched companies
- Included: Natural-language and structured screener
- Included: CSV exports
- Included: Keyed access to the /api/v1 endpoints
The free tier is real
Free
No card, no trial clock, no countdown. It is the top of the funnel and it stays useful forever. Here is exactly what it includes.
- Included: 1 therapeutic area, chosen by you
- Included: 25 rows per feed or screener query
- Included: Watch up to 5 companies
- Included: 1 seat
- Included: Full dossiers: crosswalk timeline, evidence, source filings
- Not included: Morning digest only, no instant alerts
- Not included: No screener
- Not included: No CSV export
- Not included: No API access
Before you buy
- What does an Analyst seat’s one area mean?
- You pick one therapeutic area at checkout, and the feed, the screener and the dossiers are scoped to it. Companies with no area classified yet are visible on every seat. You can switch your area from your account.
- Where does the data come from?
- Six U.S. government datasets: NIH RePORTER, ClinicalTrials.gov, SEC EDGAR, USPTO, openFDA and SBIR.gov. All public domain, all cited on every row. The full list, with refresh cadence.
- Are the numbers reliable?
- Momentum is a transparent formula over dated filings, and you can reproduce it. Runway is a model and it is labeled as one everywhere it appears. The crosswalk is a judgment call at the edges, and every dossier shows you the evidence behind it. Read the methodology before you pay.
- Is this investment advice?
- No. Biodatica publishes impersonal, generally-available research that is identical for every subscriber. We take no money from the companies we cover and we do not trade the names. Disclosures.
- Can we try it against our own thesis first?
- Yes. Start on the free tier and scan your area, or email signal@biodatica.com and we will walk the graph against a name you already know well. That is the fastest way to find out whether the crosswalk holds up.